Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Corpus Striatum | 27 | 2020 | 104 | 6.970 |
Why?
|
| Methamphetamine | 23 | 2020 | 159 | 6.310 |
Why?
|
| Receptors, Neurokinin-1 | 12 | 2011 | 25 | 2.900 |
Why?
|
| Central Nervous System Stimulants | 9 | 2020 | 174 | 1.900 |
Why?
|
| Dopamine | 9 | 2020 | 245 | 1.710 |
Why?
|
| Mice, Inbred ICR | 17 | 2017 | 40 | 1.470 |
Why?
|
| Apoptosis | 9 | 2017 | 1398 | 1.260 |
Why?
|
| Substance P | 7 | 2010 | 26 | 1.190 |
Why?
|
| Dopamine Agents | 4 | 2010 | 25 | 1.050 |
Why?
|
| Receptors, Dopamine | 3 | 2011 | 25 | 1.020 |
Why?
|
| Cocaine | 6 | 2003 | 232 | 1.010 |
Why?
|
| Nitric Oxide | 4 | 2013 | 316 | 0.970 |
Why?
|
| Dopamine Uptake Inhibitors | 5 | 2005 | 77 | 0.940 |
Why?
|
| Nerve Tissue Proteins | 8 | 2014 | 360 | 0.870 |
Why?
|
| Neurogenesis | 2 | 2014 | 58 | 0.830 |
Why?
|
| Somatostatin | 2 | 2013 | 22 | 0.820 |
Why?
|
| Protein Precursors | 9 | 2017 | 61 | 0.810 |
Why?
|
| Neuropeptide Y | 2 | 2012 | 24 | 0.800 |
Why?
|
| Tyrosine 3-Monooxygenase | 8 | 2017 | 78 | 0.780 |
Why?
|
| Neurons | 6 | 2017 | 1175 | 0.770 |
Why?
|
| Animals | 34 | 2020 | 15081 | 0.730 |
Why?
|
| Mice | 19 | 2020 | 5913 | 0.720 |
Why?
|
| Catechin | 1 | 2020 | 31 | 0.710 |
Why?
|
| Neurotoxins | 2 | 2013 | 57 | 0.700 |
Why?
|
| Membrane Glycoproteins | 5 | 2005 | 211 | 0.690 |
Why?
|
| RNA, Messenger | 10 | 2017 | 1207 | 0.680 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2013 | 35 | 0.670 |
Why?
|
| Glutamic Acid | 3 | 2020 | 128 | 0.640 |
Why?
|
| Neurotransmitter Agents | 2 | 2017 | 63 | 0.630 |
Why?
|
| Neurotensin | 2 | 2017 | 2 | 0.620 |
Why?
|
| Membrane Transport Proteins | 6 | 2020 | 95 | 0.610 |
Why?
|
| Receptors, Neurotensin | 1 | 2017 | 1 | 0.590 |
Why?
|
| Nerve Degeneration | 3 | 2006 | 107 | 0.570 |
Why?
|
| Male | 30 | 2020 | 20025 | 0.570 |
Why?
|
| Antioxidants | 1 | 2020 | 416 | 0.560 |
Why?
|
| Nucleus Accumbens | 6 | 2001 | 82 | 0.490 |
Why?
|
| Oxidative Stress | 1 | 2020 | 938 | 0.470 |
Why?
|
| Analysis of Variance | 6 | 2012 | 550 | 0.450 |
Why?
|
| Androstanes | 6 | 2011 | 7 | 0.450 |
Why?
|
| Dizocilpine Maleate | 4 | 1997 | 48 | 0.440 |
Why?
|
| Benzimidazoles | 6 | 2011 | 36 | 0.440 |
Why?
|
| Motor Activity | 2 | 2014 | 418 | 0.420 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2012 | 115 | 0.420 |
Why?
|
| Time | 1 | 2011 | 14 | 0.400 |
Why?
|
| Microinjections | 4 | 2013 | 57 | 0.400 |
Why?
|
| Dopamine Antagonists | 4 | 2011 | 44 | 0.390 |
Why?
|
| Enkephalins | 5 | 1997 | 33 | 0.380 |
Why?
|
| Presynaptic Terminals | 3 | 2005 | 53 | 0.370 |
Why?
|
| Tachykinins | 4 | 2001 | 4 | 0.360 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 6 | 2005 | 50 | 0.360 |
Why?
|
| Nitric Oxide Synthase | 1 | 2010 | 128 | 0.350 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2006 | 65 | 0.320 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2002 | 1618 | 0.310 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2001 | 107 | 0.310 |
Why?
|
| Neuropeptides | 3 | 2006 | 59 | 0.310 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2005 | 40 | 0.300 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2009 | 133 | 0.300 |
Why?
|
| Tyrosine | 3 | 2013 | 118 | 0.300 |
Why?
|
| Neuroprotective Agents | 2 | 2017 | 245 | 0.300 |
Why?
|
| Caffeine | 2 | 1997 | 28 | 0.290 |
Why?
|
| Rats | 12 | 2003 | 3483 | 0.290 |
Why?
|
| Ventral Tegmental Area | 2 | 1996 | 36 | 0.280 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 6 | 0.270 |
Why?
|
| Amphetamine | 1 | 2005 | 16 | 0.270 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 1371 | 0.270 |
Why?
|
| Cholecystokinin | 2 | 2003 | 16 | 0.260 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2005 | 70 | 0.250 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 1996 | 137 | 0.240 |
Why?
|
| Autoradiography | 5 | 2005 | 36 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 893 | 0.240 |
Why?
|
| Synapses | 1 | 2005 | 180 | 0.240 |
Why?
|
| Drug Interactions | 3 | 2012 | 141 | 0.230 |
Why?
|
| Dynorphins | 3 | 1997 | 14 | 0.210 |
Why?
|
| Tubulin | 2 | 2014 | 88 | 0.210 |
Why?
|
| Bromodeoxyuridine | 2 | 2011 | 24 | 0.200 |
Why?
|
| Acetamides | 1 | 2001 | 11 | 0.200 |
Why?
|
| Fever | 2 | 2017 | 57 | 0.190 |
Why?
|
| Time Factors | 4 | 2011 | 1742 | 0.190 |
Why?
|
| Substantia Nigra | 2 | 2001 | 44 | 0.190 |
Why?
|
| Locomotion | 1 | 2001 | 97 | 0.180 |
Why?
|
| Biological Transport | 1 | 2020 | 185 | 0.180 |
Why?
|
| Fluoresceins | 2 | 2013 | 27 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2010 | 56 | 0.170 |
Why?
|
| Brain Chemistry | 4 | 2002 | 140 | 0.170 |
Why?
|
| Endocytosis | 2 | 2010 | 113 | 0.160 |
Why?
|
| Neostriatum | 2 | 1996 | 26 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 307 | 0.160 |
Why?
|
| Brain | 2 | 2004 | 1346 | 0.160 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 2 | 2009 | 7 | 0.160 |
Why?
|
| Interneurons | 2 | 2010 | 56 | 0.160 |
Why?
|
| Benzazepines | 2 | 2011 | 32 | 0.160 |
Why?
|
| Body Temperature | 2 | 2009 | 36 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 539 | 0.140 |
Why?
|
| Mesencephalon | 1 | 1996 | 41 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2020 | 517 | 0.140 |
Why?
|
| Visual Cortex | 1 | 1997 | 60 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 112 | 0.140 |
Why?
|
| Scopolamine | 1 | 1996 | 4 | 0.140 |
Why?
|
| Muscarinic Antagonists | 1 | 1996 | 12 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2010 | 859 | 0.130 |
Why?
|
| Haloperidol | 1 | 1996 | 26 | 0.130 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1996 | 99 | 0.130 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1995 | 5 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1198 | 0.130 |
Why?
|
| Receptors, Kainic Acid | 1 | 1995 | 11 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1039 | 0.120 |
Why?
|
| Cell Count | 2 | 2005 | 135 | 0.120 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2014 | 34 | 0.120 |
Why?
|
| Parvalbumins | 1 | 2014 | 16 | 0.120 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 75 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2009 | 421 | 0.120 |
Why?
|
| Octreotide | 1 | 2013 | 2 | 0.110 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2012 | 8 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 2012 | 47 | 0.110 |
Why?
|
| Arginine | 1 | 2012 | 73 | 0.100 |
Why?
|
| Piperidines | 2 | 2002 | 77 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2012 | 207 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 23 | 0.100 |
Why?
|
| Raclopride | 1 | 2011 | 8 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 14 | 0.100 |
Why?
|
| Necrosis | 1 | 2011 | 49 | 0.100 |
Why?
|
| Dopamine Agonists | 1 | 2011 | 30 | 0.100 |
Why?
|
| Binding Sites | 2 | 2002 | 651 | 0.090 |
Why?
|
| Kinetics | 2 | 2020 | 708 | 0.090 |
Why?
|
| Immunotoxins | 1 | 2009 | 12 | 0.090 |
Why?
|
| Peptides | 1 | 2012 | 320 | 0.090 |
Why?
|
| Electrochemistry | 1 | 2009 | 34 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2009 | 98 | 0.080 |
Why?
|
| Base Sequence | 3 | 1996 | 997 | 0.080 |
Why?
|
| Endosomes | 1 | 2008 | 36 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 1996 | 1568 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2008 | 444 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 1996 | 129 | 0.070 |
Why?
|
| Synaptic Membranes | 1 | 2005 | 7 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2006 | 99 | 0.070 |
Why?
|
| Neural Pathways | 1 | 2006 | 124 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 143 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 295 | 0.060 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2005 | 73 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2004 | 35 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2003 | 4 | 0.060 |
Why?
|
| Membrane Transport Modulators | 1 | 2003 | 4 | 0.060 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2003 | 9 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2005 | 435 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 181 | 0.060 |
Why?
|
| Astrocytes | 1 | 2005 | 255 | 0.050 |
Why?
|
| Microdialysis | 1 | 2002 | 18 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 35 | 0.050 |
Why?
|
| Putamen | 1 | 2002 | 15 | 0.050 |
Why?
|
| Caudate Nucleus | 1 | 2002 | 20 | 0.050 |
Why?
|
| Pyrococcus horikoshii | 1 | 2020 | 1 | 0.050 |
Why?
|
| Proteolipids | 1 | 2020 | 3 | 0.050 |
Why?
|
| Amino Acid Transport Systems | 1 | 2020 | 5 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2020 | 47 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2020 | 212 | 0.050 |
Why?
|
| Mammals | 1 | 2020 | 105 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 364 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 289 | 0.040 |
Why?
|
| DNA Probes | 1 | 1997 | 29 | 0.040 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 22 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1997 | 177 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1995 | 23 | 0.030 |
Why?
|
| Gene Expression | 1 | 1997 | 674 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 53 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2002 | 1908 | 0.030 |
Why?
|